Is XORTX Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, XORTX Therapeutics Inc (XRTX.V) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is XORTX Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes XORTX Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of XORTX Therapeutics Inc?

Muslim investors may consider investing in XORTX Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is XORTX Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of XORTX Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for XORTX Therapeutics Inc updated?

The Shariah compliance status of XORTX Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like XORTX Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of XORTX Therapeutics Inc?

You can check the latest Shariah compliance status of XORTX Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

XRTX.V Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 18, 2026

Report Source: 2025 Annual Report

XORTX Therapeutics Inc. Stock Analysis XRTX.V

Canada Health Care Nano Cap Report: 2025 Annual

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Key Statistics of XORTX Therapeutics Inc (XRTX.V)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

CAD3.40CAD3.54

Today's Open

CAD3.50

Volume

1382.00

P/E Ratio (TTM)

52 Week Range

CAD2.42CAD9.85

Market Cap

4.16M

Avg. Volume

4953.13

Dividend Yield

Financial Metrics & Statements of XORTX Therapeutics Inc (XRTX.V)

FAQ's for XORTX Therapeutics Inc (XRTX.V)

According to Musaffa’s Shariah screening methodology, XORTX Therapeutics Inc (XRTX.V) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.